X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Cadila: poor man's Cipla - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Oct 23, 2000

    Cadila: poor man's Cipla

    Cadila Healthcare has also made its mark in the domestic pharmaceutical market thanks to the reverse engineering. The company was formed after the spilt in the partnership between the Patel and Modi groups. (The latter own Cadila Pharmaceuticals).

    (Rs m) 2QFQ00 2QFY01 Change
    Sales 1,286 1,450 12.8%
    Other Income 3 4 33.9%
    Expenditure 1,086 1,197 10.3%
    Operating Profit (EBDIT) 200 253  
    Operating Profit Margin (%) 15.6% 17.5%  
    Interest 33 (5) -113.8%
    Depreciation 11 41 274.5%
    Profit before Tax 159 221 38.6%
    Other Adjustments      
    Tax 15 30  
    Profit after Tax/(Loss) 144 191 32.3%
    Net profit margin (%) 11.2% 13.1%  
    Earnings per share* 9.68 12.80  
    (annualised)      

    At the time of the public issue, the company was positioned in the league of Cipla. However, the stock price performance has been pathetic, to say the least. The stock quotes at Rs 114 and shareholders have actually lost more than 50% of their capital if they had invested at the time of the IPO.

    The company second quarter's performance has been satisfactory vis–a–vis the growth of the overall industry. Cadila's net sales are up by 12.8% and its net profit has grown by 32.3%. The growth in post tax profit has been lead mainly by the repayment of debt which has reduced the interest cost. (To be fair to the company it has managed to improve its operating margins also, but the reduction in interest has been a key driver of earnings growth.) This is because the company still has not deployed a part of its IPO proceeds. (Of the Rs 3.72 bn that Cadila received during the time of the IPO, the company has so far utilised Rs 2.72 bn.)

    The company derives 21% from anti–infectives, 20% from gastrointestinals, 8% from cardiovascular, 10% from vaccines and 8% from anti–inflammatory. It's main brands include Ciprobid (a ciprofloxacin based anti–infective), Ocid (omeprazole based gastrointestinal), Oxalgin (diclofenac sodium based pain management) and Oriprim (trimethoprim based anti–infective).

    The stock quotes at a multiple of 9 times FY01 annualised earnings. What seems to have hit the valaution of the stock is the negative perception of the management and long drawn courtroom drama pitting the two former partners of the group. (There are as many as three court cases between the two companies at various stages of progress in the courts including the Supreme Court.)

     

     

    Equitymaster requests your view! Post a comment on "Cadila: poor man's Cipla". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    CADILA HEALTHCARE SHARE PRICE


    Aug 18, 2017 (Close)

    TRACK CADILA HEALTHCARE

    • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    MORE ON CADILA HEALTHCARE

    CADILA HEALTHCARE - GSK PHARMA COMPARISON

    Compare Company With Charts

    COMPARE CADILA HEALTHCARE WITH

    MARKET STATS